EZH2和P57在肾细胞癌中的表达及临床意义

目的检测肾细胞癌（简称肾癌）组织中EZH2和P57的表达，探讨其与肾癌临床病理特征间的关系。方法采用免疫组织化学法检测肾癌组织（n=64）和正常肾组织（n=12）中EZH2和P57的表达，分析EZH2和P57表达与’肾癌临床病理特征间的关系及其二者表达的相关性。结果正常。肾组织EZH2及P57蛋白的阳性表达率分别为16．67％和75．00％：肾癌组织EZH2和P57的阳性表达率为78．13％和25．56％，肾癌组织EZH2阳性表达率高于正常肾组织，P57阳性表达率低于正常肾组织（均P〈0．01）。EZH2阳性表达率随肾癌临床分期和病理分级升高而增加，且淋巴结转移组EZH2阳性表达水平明显高于无淋巴结转移组；P57阳性表达率随肾癌临床分期和病理分级升高而呈下降趋势，且淋巴结转移组P57表达水平低于无淋巴结转移组。二者差异表达与患者的性别及年龄均无关（均P〉0．05）。相关性分析显示：P57和EZH2在肾癌组织中的表达呈显著负相关（r=-0．648，P〈0．05）。结论EZH2和P57异常表达与肾癌发生和临床进展关系密切，P57可能是EZH2的下游靶基因，但其靶向抑制的具体机制尚需要深入研究。

Expression of EZH2 and P57 in Renal Cell Carcinoma and Its Clinical Significance

Objective To investigate the relationship of the expression of EZH2 and P57 to the clinicopathologie characteristics in renal cell carcinoma（RCC）. Methods The expression of EZH2 and P57 protein in RCC tissues（n=64）and normal renal tissues（n=l 2） were detected by immunohistochemistry. The relationship between the expression of EZH2 and P57 and the clinicopathologic characteristics was analyzed. Furthermore, the correlation between EZH2 and P57 was analyzed. Results Compared with normal renal tissues, the positive expression rate of EZH2 increased but the positive expression rate of P57 decreased in RCC tissues （16.67% vs 75.00% and 78.13% vs 25.56%, respectively; P〈0.01 ）. EZH2 expression was positively associated with clinical stage, pathological grade and lymph node metastasis. However, P57 expression was negatively associated with clinical stage, pathological grade and lymph node metastasis, The expression of EZH2 and P57 was not related to the gender and age （P〉0.05）. There was a negative correlation between P57 and EZH2 expression in RCC tissues （r=-0.648, P〈0.05）. Conclusion The abnormal expression of EZH2 and P57 plays a crucial role in the occurrence and development of RCC. P57 may be a downstream target of EZH2. However, the mechanisms of targeting inhibition need to be further studied.